The clinical effect of Oxaliplatin in patients with primary hepatocellular carcinoma after transcatheter arterial chemoembolization
10.3760/cma.j.issn.0254-9026.2018.03.011
- VernacularTitle:奥沙利铂联合肝动脉化疗栓塞术治疗老年原发性肝癌患者的临床疗效
- Author:
Yun CAO
1
;
Wei LI
;
Kuihua XU
Author Information
1. 233003,安徽蚌埠医学院第一附属医院感染科
- Keywords:
Oembolization,therapeutic;
Liver neoplasms
- From:
Chinese Journal of Geriatrics
2018;37(3):288-290
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy and safety of Oxaliplatin combined with transcatheter arterial chemoembolization in the treatment of elderly patients with primary hepatocellular carcinoma.Methods One-hundred and three elderly patients with primary hepatocellular carcinoma who were treated in First Affiliated Hospital of Bengbu Medical College from January 2013 to July 2017 were selected.Based on the treatment methods,all patients were divided into the observation group and the control group by random number table method.Patients in the observation group (n=51) were treated with transcatheter arterial chemoembolization combined with Oxaliplatin,and those in the control group (n =52) treated with traditional hepatic arterial chemoembolization.The clinical efficacy and adverse reactions were compared and analyzed between groups.Results In the observation group,the partial remission rate (70.6％ vs.50％,x2 =4.555,P=0.033) and the total effective rate (72.6％ vs.50％,x2 =5.511,P=0.019) were significantly higher than those in the control group.Additionally,there was no significant difference in the incidence of adverse reactions between the two groups (all P＞0.05).Conclusions Combined with transcatheter arterial chemoembolization,Oxaliplatin could safely and effectively improve the prognosis of elderly patients with primary hepatocellular carcinoma..
